NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of ...

SAN DIEGO - Calidi Biotherapeutics, Inc. (NYSE American:CLDI), currently trading at $1.09 per share with a market capitalization of $11.25 million, announced Wednesday it has entered into a ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.